India and China as partner of choice for the Western multinational companies in the era of globalisation
by Rakhi Rashmi
International Journal of Learning and Intellectual Capital (IJLIC), Vol. 8, No. 2, 2011

Abstract: By the Patent Amendment Act 2005, India approved Trade Related Aspect of Intellectual Property Rights (TRIPs) Agreement of the World Trade Organization (WTO) and implemented product patent protection for pharmaceutical and biopharmaceutical products. China, too, at the end of 2002 enacted regulations to strengthen pharmaceutical and biopharmaceutical patents. The change in the patent regimes demand that both these countries biopharmaceutical industries which are basically generic industries to shift from generic manufacturing to novel drug manufacturing. Although due to generic manufacturing base, these countries are able to offer cost-efficient discovery research, testing and manufacturing support to western multinationals. On the other hand, the rising cost and continuous risk involved in drug development process making the western MNCs to head towards Asia for collaboration. The paper explores the best partner of choice between India and China for the multinational companies by analysing the relative strength of the parameter suggested by John Dunning for making the foreign investment.

Online publication date: Thu, 27-Nov-2014

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Learning and Intellectual Capital (IJLIC):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com